Gastric Cancer
Gastric Cancer
Advertisement
Emily MenendezGastric Cancer | October 30, 2024
The SOX chemotherapy regimen for gastric cancer consists of S-1, an oral fluoropyrimidine, in combination with oxaliplatin.
Read More
Brandon TwyfordGastric Cancer | October 22, 2024
Tislelizumab shows significant survival benefits in first-line treatment for gastric and esophageal cancers.
Laura LitwinGastric Cancer | October 18, 2024
FDA approval of the first and only CLDN18.2-targeted treatment follows two successful phase III clinical trials.
Trevor Leong, MDGastric Cancer | September 18, 2024
Dr. Leong showcases the highly anticipated results of the TOPGEAR study in patients with resectable G/GEJ adenocarcinoma.
Zachary BessetteGastric Cancer | September 17, 2024
The addition of preop CRT to periop chemo may not have added OS benefit for patients with resectable G/GEJ adenocarcinoma.
Zev Wainberg, MD, MScGastric Cancer | September 30, 2024
Dr. Wainberg reviews the data on GI malignancies and notes that it is unclear who should receive radiation before surgery.
Yelena Janjigian, MDGastric Cancer | September 16, 2024
Dr. Janjigian shares an overview of the DESTINY-Gastric03 study and the history of T-Dxd for gastric and GEJ cancers.
Brandon TwyfordGastric Cancer | September 16, 2024
Trastuzumab deruxtecan, pembrolizumab, and chemotherapy shows benefits in advanced or metastatic esophageal, gastric, or GEJA
Zachary BessetteGastric Cancer | September 11, 2024
These data may support the approval of pembro plus trastuzumab and chemo in patients with HER2+ metastatic G/GEJ cancer.
Emily MenendezGastric Cancer | August 30, 2024
Researchers utilized a deep learning model to combine data and develop personalized treatment response predictions.
Nina Sanford, MDGastric Cancer | August 13, 2024
Dr. Sanford shares unique experiences and insights on her life and career in this interview with GI Oncology Now.
Katy MarshallGastric Cancer | August 2, 2024
Currently, there is little research on the comparative accuracy of mpMRI versus DECT.
Grace-Ann Fasaye, ScM, CGCGastric Cancer | July 25, 2024
Grace-Ann Fasaye discusses the elevated lifetime risk of gastric cancer in patients with CDH1 gene variants.
Katy MarshallGastric Cancer | July 18, 2024
Researchers reported that a buildup of lactate was most notable in chemotherapy-resistant cancer tissues.
Nataliya Uboha, MD, PhDGastric Cancer | July 2, 2024
Drs. Uboha and Karasic discuss the benefits and considerations of treating gastric cancer with an anti-CCR8 antibody.
Katy MarshallGastric Cancer | July 15, 2024
The study’s primary endpoint was the connection between OS and post-recurrence survival.
David H. Ilson, MD, PhDGastric Cancer | June 24, 2024
Drs. David H. Ilson and Nataliya Uboha highlight the final OS results of the phase 3 SPOTLIGHT study.
Emily MenendezGastroesophageal Cancer | July 15, 2024
Claudin 18 isoform 2 is an emerging therapeutic target in gastric and gastroesophageal cancers.
Brandon TwyfordGastric Cancer | June 18, 2024
Phase 3 IKF-575/RENAISSANCE trial shows surgery after FLOT may benefit RPLN-only metastatic gastric cancer patients.
Emily MenendezGastric Cancer | June 5, 2024
Switch maintenance may extend the benefits of an initial treatment strategy and can delay clinical deterioration.
Advertisement
Advertisement
Advertisement
Latest News

October 30, 2024